1-Minute Pearls/Pitfalls for the Clinician.

Area of Science:

• Pharmacology
• Nephrology
• Oncology

Background:

• Adverse drug reactions, including electrolyte imbalances, are common in clinical practice.
• Trimethoprim-sulfamethoxazole (Bactrim) is frequently used for Pneumocystis pneumonia (PJP) prophylaxis.
• Immune checkpoint inhibitors (ICIs) are increasingly used in cancer therapy, with potential for unique toxicities.

Purpose of the Study:

• To review the pearls and pitfalls in managing hyperkalemia associated with Bactrim.
• To discuss strategies for addressing hypercalcemia induced by ICIs.

Main Methods:

• Literature review of clinical guidelines and case reports.
• Analysis of mechanisms of electrolyte disturbances.
• Synthesis of management strategies.

Main Results:

• Bactrim can cause dose-dependent hyperkalemia by inhibiting renal potassium excretion.
• Hypercalcemia associated with ICIs can be severe and requires prompt management.
• Management strategies involve drug discontinuation, supportive care, and specific treatments.

Conclusions:

• Proactive monitoring and management are crucial for patients on Bactrim for PJP prophylaxis.
• Early recognition and intervention are key for managing ICI-induced hypercalcemia.
• Understanding these specific toxicities improves patient outcomes in infectious disease and oncology settings.